Archived AES Symposia 2006
Plenary Session: Mortality
Program Length: 1 hrs 52 min
Some seizure disorders are known to be associated with excess mortality, and persons with epilepsy have been reported to have shorter life expectancies. Furthermore, concerted attention from both clinicians and researchers is needed to address the catastrophic condition of sudden unexplained death in epilepsy (SUDEP). This program will identify epileptic conditions that are associated with increased risks for death, so that measures can be formulated and applied to reduce the risks. The necessity and the implications of counseling patients about the risk of SUDEP will also be discussed.
At the conclusion of this activity, participants should be able to:
- Given that some epileptic disorders are associated with increased mortality, identify patients whose conditions are associated with increased mortality in order to optimize individual care
- For the healthcare professional and neurologist, identify patient activities and types of seizures that are associated with increased risk of serious accidental injuries and educate patients regarding these risks
- Given the high risk of SUDEP in some epilepsy patients, identify and provide appropriate preventive measures to patients
- Given the ethical and legal implications of disclosing the risk of death to an epilepsy patient, identify clinical situations when such disclosure may be necessary in order to address patient and caregiver concerns.
Neurologists, nurses, pharmacists, epidemiologists and other healthcare professionals involved in the care of persons with epilepsy.
Program FacultyChair: Elson L. So, M.D.
Mortality and Life Expectancy in Persons with Epilepsy
Anne T. Berg, Ph.D.
Accidental Death in Epilepsy
Elaine C. Wirrell, M.D., FRCP
SUDEP: Risk Factors and Prevention
Torbjörn Tomson, M.D.
Disclosures and Counseling: Ethical and Legal Implications
Tess L. Sierzant, RN, M.S.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.